Macrolides as immunomodulatory medications for the therapy of chronic lung diseases

Current Opinion in Pharmacology

Volumn 8, Issue 3, 2008, Pages 286-291

  López Boado, Yolanda S ^a   Rubin, Bruce K ^b  

^a GLAXOSMITHKLINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BETA DEFENSIN; CLARITHROMYCIN; CLAUDIN; CORTICOSTEROID; CYCLOSPORIN; EM 703; EPITHELIAL SODIUM CHANNEL; ERYTHROMYCIN; ERYTHROMYCIN DERIVATIVE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; JOSAMYCIN; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 5AC; OCCLUDIN; PLACEBO; ROXITHROMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR AP 1; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHIOLITIS; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; CYTOKINE RELEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; GRAFT REJECTION; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; LUNG FIBROSIS; LUNG INFECTION; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ASTHMA; CHRONIC DISEASE; CYSTIC FIBROSIS; DEFENSINS; EPITHELIAL CELLS; HUMANS; IMMUNOLOGIC FACTORS; ION TRANSPORT; LUNG DISEASES; MACROLIDES; MUCUS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 44649152300     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.01.010     Document Type: Review

References (57)

1. Tateda K., Standiford T.J., Pechere J.C., and Yamaguchi K. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. Curr Pharm Des 10 (2004) 3055-3065
2. Labro M.T. Macrolide antibiotics: current and future uses. Expert Opin Pharmacother 5 (2004) 541-550
3. Shinkai M., and Rubin B.K. Macrolides and airway inflammation in children. Paediatr Respir Rev 6 (2005) 227-235
4. Henke M.O., Shah S.A., and Rubin B.K. The role of airway secretions in COPD - clinical applications. COPD 2 (2005) 377-390
5. Rubin B.K., and Henke M.O. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 125 (2004) 70S-78S
6. Johnston S.L. Macrolide antibiotics and asthma treatment. J Allergy Clin Immunol 117 (2006) 1233-1236
7. Parnham M.J. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 18 (2005) 125-131
8. Giamarellos-Bourboulis EJ: Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008, 31:12-20.
9. Callard R., George A.J., and Stark J. Cytokines, chaos, and complexity. Immunity 11 (1999) 507-513
10. Shinkai M., Foster G.H., and Rubin B.K. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 290 (2006) L75-L85
11. Shinkai M., Lopez-Boado Y.S., and Rubin B.K. Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin. J Antimicrob Chemother 59 (2007) 1096-1101. This was one of the first papers demonstrating that the effect of low dose macrolides is truly immunomodulatory rather than anti-inflammatory, and that this was mediated, in part, by the ERK pathway, confirming earlier work (reference [10]).
12. Shinkai M., Tamaoki J., Kobayashi H., Kanoh S., Motoyoshi K., Kute T., and Rubin B.K. Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression. Antimicrob Agents Chemother 50 (2006) 1738-1744
13. Kadota J., Mukae H., Ishii H., Nagata T., Kaida H., Tomono K., and Kohno S. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 97 (2003) 844-850
14. •] illustrate the effect and doses of macrolides used in the clinic in DPB and CF.
15. Culic O., Erakovic V., and Parnham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 429 (2001) 209-229
16. Schultz M.J. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother. (2004) 21-28
17. Tsai W.C., and Standiford T.J. Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. Curr Pharm Des 10 (2004) 3081-3093
18. Shinkai M, Henke MO, Rubin BK: Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharm Therap 2008, 117:393-405.
19. Culic O., Erakovic V., Cepelak I., Barisic K., Brajsa K., Ferencic Z., Galovic R., Glojnaric I., Manojlovic Z., Munic V., et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 450 (2002) 277-289
20. Parnham M.J., Culic O., Erakovic V., Munic V., Popovic-Grle S., Barisic K., Bosnar M., Brajsa K., Cepelak I., Cuzic S., et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol 517 (2005) 132-143. This study shows that in vivo, azithromycin can initially increase the elaboration of inflammatory mediators followed by a sustained decrease in inflammation, as is characteristic of immunomodulation.
21. Ivetic T.V., Bosnjak B., Hrvacic B., Bosnar M., Marjanovic N., Ferencic Z., Situm K., Culic O., Parnham M.J., and Erakovic V. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur J Pharmacol 539 (2006) 131-138
22. Giamarellos-Bourboulis E.J., Adamis T., Laoutaris G., Sabracos L., Koussoulas V., Mouktaroudi M., Perrea D., Karayannacos P.E., and Giamarellou H. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 48 (2004) 93-99
23. Legssyer R., Huaux F., Lebacq J., Delos M., Marbaix E., Lebecque P., Lison D., Scholte B.J., Wallemacq P., and Leal T. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res 7 (2006) 134. It is thought that CF lung disease is due, in part, to a hyper-inflammatory state, with both constitutive inflammation and the induced inflammatory response being increased. This study demonstrates that azithromycin can 'reset' (modulate) both the spontaneous and the induced inflammatory response in a mouse model of CF.
24. Bosnar M., Kelneric Z., Munic V., Erakovic V., and Parnham M.J. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother 49 (2005) 2372-2377
25. Hodge S., Hodge G., Brozyna S., Jersmann H., Holmes M., and Reynolds P.N. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J 28 (2006) 486-495
26. •]).
27. Hodge S., Hodge G., Scicchitano R., Reynolds P.N., and Holmes M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 81 (2003) 289-296
28. Hodge S., Hodge G., Ahern J., Jersmann H., Holmes M., and Reynolds P.N. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in COPD. Am J Respir Cell Mol Biol 37 (2007) 748-755
29. Li Y.J., Azuma A., Usuki J., Abe S., Matsuda K., Sunazuka T., Shimizu T., Hirata Y., Inagaki H., Kawada T., et al. EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts. Respir Res 7 (2006) 16. This study demonstrates that a powerfully immunomodulatory 14-member macrolide derivative can actually hasten resolution of bleomycin-induced lipid peroxidation injury and fibrosis. This is also a remarkable paper because EM703 is a derivative of erythromycin A that has no identifiable antimicrobial properties.
30. Ikeda H, Sunazuka T, Suzuki H, Hamasaki Y, Yamazaki S, Omura S, Hatamochi A: EM703, the new derivative of erythromycin, inhibits transcription of type I collagen in normal and scleroderma fibroblasts. J Dermatol Sci 2008, 49:195-205.
31. Cigana C., Assael B.M., and Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 51 (2007) 975-981
32. Cigana C., Nicolis E., Pasetto M., Assael B.M., and Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 350 (2006) 977-982
33. Desaki M., Okazaki H., Sunazuka T., Omura S., Yamamoto K., and Takizawa H. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation. Antimicrob Agents Chemother 48 (2004) 1581-1585. This paper illustrates the molecular mechanisms of macrolide activity in a lung epithelial cells line, including the non-antimicrobial erythromycin derivative EM703.
34. Yamasawa H., Oshikawa K., Ohno S., and Sugiyama Y. Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. Am J Respir Cell Mol Biol 30 (2004) 569-575
35. Takizawa H., Desaki M., Ohtoshi T., Kawasaki S., Kohyama T., Sato M., Tanaka M., Kasama T., Kobayashi K., Nakajima J., et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 156 (1997) 266-271
36. Sunazuka T., Takizawa H., Desaki M., Suzuki K., Obata R., Otoguro K., and Omura S. Effects of erythromycin and its derivatives on interleukin-8 release by human bronchial epithelial cell line BEAS-2B cells. J Antibiot (Tokyo) 52 (1999) 71-74
37. Mauad T., and Dolhnikoff M. Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 14 (2008) 31-38
38. Holgate S.T. The airway epithelium is central to the pathogenesis of asthma. Allergol Int 57 (2008) 1-10
39. Vos J.B., Datson N.A., Rabe K.F., and Hiemstra P.S. Exploring host-pathogen interactions at the epithelial surface: application of transcriptomics in lung biology. Am J Physiol Lung Cell Mol Physiol 292 (2007) L367-L377
40. Randell S.H., and Boucher R.C. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 35 (2006) 20-28. This is an excellent recent review on mucociliary clearance and its critical role for normal lung function.
41. Shimizu T., Shimizu S., Hattori R., Gabazza E.C., and Majima Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med 168 (2003) 581-587
42. Kaneko Y., Yanagihara K., Seki M., Kuroki M., Miyazaki Y., Hirakata Y., Mukae H., Tomono K., Kadota J., and Kohno S. Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis. Am J Physiol Lung Cell Mol Physiol 285 (2003) L847-L853
43. Sperandio V. Novel approaches to bacterial infection therapy by interfering with bacteria-to-bacteria signaling. Expert Rev Anti Infect Ther 5 (2007) 271-276
44. Swords W.E., and Rubin B.K. Macrolide antibiotics, bacterial populations and inflammatory airway disease. Neth J Med 61 (2003) 242-248
45. Imamura Y., Yanagihara K., Mizuta Y., Seki M., Ohno H., Higashiyama Y., Miyazaki Y., Tsukamoto K., Hirakata Y., Tomono K., et al. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells. Antimicrob Agents Chemother 48 (2004) 3457-3461
46. Kim D.Y., Takeuchi K., Ishinaga H., Kishioka C., Suzuki S., Basbaum C., and Majima Y. Roxithromycin suppresses mucin gene expression in epithelial cells. Pharmacology 72 (2004) 6-11
47. Gorrini M., Lupi A., Viglio S., Pamparana F., Cetta G., Iadarola P., Powers J.C., and Luisetti M. Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics. Am J Respir Cell Mol Biol 25 (2001) 492-499
48. Park J.A., He F., Martin L.D., Li Y., Chorley B.N., and Adler K.B. Human neutrophil elastase induces hypersecretion of mucin from well-differentiated human bronchial epithelial cells in vitro via a protein kinase C{delta}-mediated mechanism. Am J Pathol 167 (2005) 651-661
49. Shao M.X., and Nadel J.A. Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme. J Immunol 175 (2005) 4009-4016
50. Pradal U., Delmarco A., Morganti M., Cipolli M., Mini E., and Cazzola G. Long-term azithromycin in cystic fibrosis: another possible mechanism of action?. J Chemother 17 (2005) 393-400
51. Ge N., Nakamura Y., Nakaya Y., and Sone S. Interferon-gamma activates outwardly rectifying chloride channels in the human bronchial epithelial cell line BEAS-2B. J Med Invest 48 (2001) 97-101
52. Barker P.M., Gillie D.J., Schechter M.S., and Rubin B.K. Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium. Am J Respir Crit Care Med 171 (2005) 868-871. This paper demonstrates that macrolides do not have a significant effect on epithelial ion transport, so it is unlikely that the beneficial effects of macrolides are mediated by this mechanism.
53. Laube D.M., Yim S., Ryan L.K., Kisich K.O., and Diamond G. Antimicrobial peptides in the airway. Curr Top Microbiol Immunol 306 (2006) 153-182
54. Ishizawa K., Suzuki T., Yamaya M., Jia Y.X., Kobayashi S., Ida S., Kubo H., Sekizawa K., and Sasaki H. Erythromycin increases bactericidal activity of surface liquid in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 289 (2005) L565-L573. This report shows that macrolides can increase epithelial antimicrobial activity in the absence of inflammation, suggesting that macrolide treatment may contribute to improvement of the epithelial barrier function and defense against microorganisms by this mechanism.
55. Hiratsuka T., Mukae H., Iiboshi H., Ashitani J., Nabeshima K., Minematsu T., Chino N., Ihi T., Kohno S., and Nakazato M. Increased concentrations of human beta-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax 58 (2003) 425-430
56. Asgrimsson V., Gudjonsson T., Gudmundsson G.H., and Baldursson O. Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob Agents Chemother 50 (2006) 1805-1812. This recent report suggests a novel action of macrolides in maintenance of the epithelial barrier integrity.
57. Gao X., Ray R., Xiao Y., Barker P.E., and Ray P. Inhibition of sulfur mustard-induced cytotoxicity and inflammation by the macrolide antibiotic roxithromycin in human respiratory epithelial cells. BMC Cell Biol 8 (2007) 17